CompletedNot applicableNCT05016037
Predictors of Speech Ability in Down Syndrome
Studying Down syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt University Medical Center
- Principal Investigator
- Stephen Camarata, PhDVUMC Dept of Hearing & Speech Sciences
- Intervention
- Lexically based speech recast(behavioral)
- Enrollment
- 18 enrolled
- Eligibility
- 4-17 years · All sexes
- Timeline
- 2022 – 2025
Study locations (1)
- VUMC Bill Wilkerson Center, Nashville, Tennessee, United States
Collaborators
National Institute on Deafness and Other Communication Disorders (NIDCD)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05016037 on ClinicalTrials.govOther trials for Down syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07416201Natural History of Dysregulation and Aging of the Immune System in People With Trisomy 21 With and Without ThymectomyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNANCT07484464Effects of the Otago Exercise Program on Balance, Endurance, and Motor Coordination in Children With Down SyndromeRiphah International University
- RECRUITINGNCT07195253Oro-myofunctional Characteristics and Obstructive Sleep Apnea in Infants With Down SyndromeHospices Civils de Lyon
- RECRUITINGNANCT07296861HomeGrown: A Family-based Lifestyle Intervention to Support Healthy Development of Young Children With Down SyndromeUNC Lineberger Comprehensive Cancer Center
- RECRUITINGNANCT07425769Adapting RDAD for DSUniversity of Kansas Medical Center
- RECRUITINGPHASE4NCT07280468Endotype DIrected Treatment for OSA in Down SyndromeUniversity of Arizona
- ENROLLING BY INVITATIONNCT07413224Qualitative Effects of AEF0217 in Down Syndrome PeopleAelis Farma
- RECRUITINGPHASE2NCT07242638Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeIcahn School of Medicine at Mount Sinai